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Background: Chemoprevention could significantly reduce cancer burden. Assessment of efficacy and 
risk/benefit balance is at best achieved through randomized clinical trials. 
Methods: At a periodic health examination center 1463 adults were asked to complete a questionnaire about their 
willingness to be involved in different kinds of preventive clinical trials.  
Results: Among the 851 respondents (58.2%), 228 (26.8%) agreed to participate in a hypothetical chemopreven-
tion trial aimed at reducing the incidence of lung cancer and 116 (29.3%) of 396 women agreed to a breast cancer 
chemoprevention trial. Randomization would not restrain participation (acceptability rate: 87.7% for lung cancer 
and 93.0% for breast cancer). In these volunteers, short-term trials (1 year) reached a high level of acceptability: 
71.5% and 73.7% for lung and breast cancer prevention respectively. In contrast long-term trials (5 years or more) 
were far less acceptable: 9.2% for lung cancer (OR=7.7 CI95% 4.4-14.0) and 10.5 % for breast cancer (OR=6.9 CI95% 
3.2-15.8). For lung cancer prevention, the route of administration impacts on acceptability with higher rate 53.1% 
for a pill vs. 7.9% for a spray (OR=6.7 CI95% 3.6-12.9).  
Conclusion: Overall healthy individuals are not keen to be involved in chemo-preventive trials, the design of 
which could however increase the acceptability rate.  
Key words: Research Design, Randomized Controlled Trials, Behavior, Attitude, Preventive Health Services, Prevention & 
Control, Neoplasms, Breast, Lung 
Introduction 
Cancer control requires therapeutic and preven-
tive innovations. Biomedical ‘upstream’ actions like 
vaccination [1] or chemoprevention [2] could signifi-
cantly reduce cancer burden. 
Efficacy, risks and benefits of such interventions 
are currently assessed by different means, of which 
randomized clinical trial is the gold standard. For 
preventive purposes this methodology requires (with 
respect to the annual rate of end-points) a large num-
ber of person-years in order to reach a fair discrimi-
natory power.  
In an ongoing randomized trial comparing two 
screening strategies we observed that 1000 persons 
had been interviewed in order to enroll 1.4 persons 
where 9 were eligible [3]. Based-on that experience we 
wanted to have more information on critical factors 
that will help to increase that (low) acceptation rate. 
We decided to come back to the same population 
having been offered an actual screening trial asking 
them their opinion about different modalities of a fu-
ture preventive trial. When considering the feasibility 
of such trials in the general population, information 
regarding the absolute and differential rates of ac-
ceptability according to different study designs repre-
sent valuable data.  
Survey based on questionnaire or observed par-
ticipation rate usually focused on patient perspectives: 
the impact of actual and perceived risk of being af-
fected [4], the fear of side effects [5], psychological 
factors among which “worry” [6], demographic [7], 
and socio cultural or ethnic criteria [8]. The effect of 
physician recommendation also had been assessed 
[6,9]. All these factors impact on persons’ decision and 
multiple barriers exist [8]. We assumed that besides Int. J. Med. Sci. 2008, 5 
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these characteristics, different study designs are also 
relevant factors to consider. 
Materials and Methods 
The administrative organization within France 
relies on Regions: 25 with a mean population of about 
2 400 000 inhabitants; range: 160 000 (Guyane)-11 000 
000 (Ile de France). In almost every Region, the French 
National Health Insurance (Caisse National 
d’Assurance Maladie) set up a “Health Center” 
(“Centre de Sante”) to promote prevention and 
screening of diseases. Once every 5 years, these centers 
sent invitations to all affiliated persons (working peo-
ple, former or retired workers and their families). For 8 
years now, invitations are extended to the whole 
population living in France through the Universal 
Health Coverage System (“Couverture Medicale Uni-
verselle”). 
We carried out a descriptive survey in the peri-
odic health center located in Marseilles France. Be-
tween January 2003 and May 2003, we included con-
secutive clients (both women and men) over the legal 
age of 18 who agreed to participate in the survey.  
Subjects were given a written description of the 
survey and were asked to complete, on site, a three 
part self-administrated questionnaire. The responses 
were elicited on a sheet of paper.  
The first part recorded the socio-demographic 
variables and some general information (familial his-
tory, belief in the efficacy of treatments…). The second 
investigated the willingness to participate in a lung 
cancer chemoprevention trial depending on different 
design options: randomization, trial duration (years), 
and route of administration for lung cancer prevention 
(pill versus spray). The third part, intended for women 
only, investigated the willingness to participate in a 
breast cancer chemoprevention trial with the same 
design options. The questionnaire was built after a 
pilot phase with a face-to-face interview of 98 persons 
(these questionnaires were not used in the analysis 
presented). 
One critical ethical issue about clinical trials is the 
acceptability of randomization and how lay people 
understand it [10]. In our questionnaire that issue was 
framed as: “To test the actual efficacy of a drug among 100 
persons, 50 will receive the drug and 50 will receive a drug 
without effect (i.e. a pill that looks the same but is ineffec-
tive). Knowing that, would you still agree to participate in 
this trial?” This wording had been upheld after the 
pilot phase designed to increase actual understanding 
and to decrease the impact of how the question was 
phrased [11]. Information about the meaning of ran-
domization was also disclosed in the initial informa-
tion sheet that described the offer to participate in the 
survey. 
Social desirability bias cannot however been ex-
cluded [12].  
CHI2 statistic tests (two-sided) and logistic re-
gression were computed using SPSS v11.0. For women, 
willingness to participate in a trial (breast or lung 
cancer prevention) has been tested for correlation with 
willingness to participate in the other study (lung or 
breast), to have a quantitative assessment of this rela-
tionship and also, due to the concept of preferential 
risk aversion, whereby some individuals may be re-
luctant to participate in some kinds of trial but agree 
for different circumstances [13]. The other main a priori 
was that family history of a cancer might be an impe-
tus to become involved in a preventive clinical trial. 
The aim of this survey was to obtain descriptive 
data, and the results should be seen as preliminary but, 
from our perspective, will help to raise hypotheses 
deserving to be tested. Since no explicative goals were 
pursued no sample size was calculated [14]. 
The survey has been carried out according to the 
French legislation related to medical research and did 
not require a National or local IRB approval since data 
were strictly anonymous. Taking in account the advice 
of a local Ethical Board, an information sheet was de-
livered to the clients of the Periodic Health Center. The 
client returned (or didn’t) the questionnaire filled or 
unfilled without any intervention of the staff aiming at 
increasing the response rate.  
Results 
During the recruitment period, 1463 question-
naires were distributed at the health examination cen-
ter, 545 questionnaires were not returned or blank 
(without either explication or comment from the 
non-responding individuals), 918 (63%) were com-
pleted. Partial respondents and subjects who declared 
a personal cancer history were excluded. The statistical 
analysis was carried out on 851 questionnaires (re-
sponse rate 58 %). The main characteristics of the 
sample are: 429 male (50.5%); mean age: 45.2 y; 36.5% 
with college graduation or higher and 234 current 
smokers (27.8%). 
Among the 851 respondents, 228 (26.8%) would 
agree to participate in a lung cancer chemoprevention 
trial. Men (31.9%) agreed more often than women 
(21.4%) OR=1.7 95%CI 1.2-2.4. Using univariate analy-
sis among men, tobacco exposure was the only factor 
associated with the willingness to participate (OR=2.3 
95%CI 1.4-3.9). In a multivariate analysis among 
women, for lung cancer two factors were associated 
with a higher rate: agreement to participate in breast Int. J. Med. Sci. 2008, 5 
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cancer prevention trial (OR=84.3 95%CI 36.6-193.8) and 
being single (OR=2.2 95%CI 1.1-4.6).  
Among 396 women, 116 (29.3%) declared agree-
ment to participate in a breast cancer chemoprevention 
trial. Three factors were associated  with agreement: 
willingness to participate in a lung cancer prevention 
trial (OR=103 95%CI 43-247), positive familial history 
of breast cancer (OR=3.2 95%CI 1.4-6.9), and trust in 
therapeutic efficacy (OR=2.1 95%CI 1.0-4.2) (table 1).  
Table 1 Individual factors associated with the willingness to be 
involved in a preventive clinical trial. (Multivariate analysis 
using logistic regression)  
Options Person’s 
positions 
Lung cancer 
prevention 
male N=429 * 
Lung cancer 
prevention 
female N=378
Breast 
cancer 
preven-
tion  
N=373 
Tobacco expo-
sure 
Yes ver-
sus no 
OR 2.3 
(1.4-3.9) 
NS   NS 
Willingness to 
be involved in 
an other pre-
ventive trial 
Yes ver-
sus no 
NA OR  84.3 
(36.6-193.8) 
OR 103  
(43-247) 
Familial history 
of related cancer 
Yes ver-
sus no 
NS NS    OR  3.2 
(1.4-6.9) 
Trust in the 
therapeutic 
efficacy 
Yes ver-
sus no 
NS NS    OR  2.1 
(1.0-4.2) 
Being single  Yes ver-
sus no 
NS OR  2.2 
(1.1.-4.6)  
NS 
Older Age **  Yes ver-
sus no 
NS NS    NS 
Higher Educa-
tional level *** 
Yes ver-
sus no 
NS NS NS 
* Univariate analysis (Chi2), since only one factor was found sig-
nificant, no multivariate analysis was carried out 
**1 Above the lower quartile i.e. above 29 y old for the pooled 
population and above 31 y for female population (the case of breast 
cancer prevention)  
***2 College or higher 
 
 
The main result of this survey was that the level 
of acceptability exhibits huge differences according to 
the design of the trial (table 2). In the sub-group of 
volunteers, we observed a high acceptability rate for 
randomization: 87.7% for lung cancer and 93.0% for 
breast cancer. Short term trials (1 year) reached a high 
level of acceptability with 71.5% and 73.7% for lung 
and breast cancer prevention respectively, while long 
term trials (5 years or more) were far less acceptable: 
9.2% for lung cancer (OR=7.7 95%CI 4.4-14.0) and 10.5 
% for breast cancer (OR=6.9 95%CI 3.2-15.8).  
Among the 851 males and females, only 21 per-
sons (2.5%) would agree to be randomized in a clinical 
trial looking at lung cancer prevention lasting 5 years 
or more. Among the 396 women in our sample only 12 
(3.0%) would agree with a similar long-term trial for 
breast cancer prevention.  
For lung cancer the route of administration of the 
active product made a difference, with a higher ac-
ceptability rate of an “ubiquitous” pill: 53.1%, far 
higher than the “disease-specific” spray 7.9% (OR=6.7 
95%CI 3.6-12.9). 
Table 2 Impact of the design of the trial on the acceptability rate 
in volunteers for a chemo-preventive trial. 
Options Person’s 
positions 
Lung cancer 
prevention 
N=228 
Breast cancer 
prevention 
N=114* 
Agree  200 (87.7%)  106 (93.0%)  Randomization 
Disagree 
 
22 (9.6%)  8 (7.0%) 
1 y or less  163 (71.5%) **  84 (73.7%) *** 
2-3 y  24 (10.5%)  10 (8.8%) 
Time length 
(Trial duration) 
 
  5 y or more  21 (9.2%)  12(10.5%) 
Pill  121 (53.1%) **** - 
Spray 18  (7.9%)  - 
Kind of treatment
(Route of admini-
stration)  Indifferent 
 
77 (33.8%)  - 
* Among the 116 women who agreed to be involved in a 
chemo-preventive trial, 114 filled the part of the questionnaire re-
garding the trial options.  
* for lung cancer prevention. Difference between 1 year or less and 5 
years or more OR=7.7 95% CI 4.4-14.0  
** for breast cancer prevention. Difference between 1 year or less and 
5 years or more OR=6.9 95% CI 3.2-15.8 
*** for lung cancer prevention. Difference between “a pill” and “a 
spray” OR=6.7 95% IC 3.6-12.9 
Discussion  
On average, regardless the kind of survey, ac-
ceptability rate is low and may even be lower in the 
non-respondents group due to psychological or social 
differences [15]. This low rate has been reported in 
various survey, 34.0% for breast cancer prevention 
(actual trial) [6] or even lower 22.1% (willingness to 
participate) [7].   
These data contrast with highly accepted and 
performed chemoprevention of cardiovascular dis-
eases [16]. Already in the late eighties, 84% of the per-
sons with hypertension were aware of it, 73% under 
treatment and 55% controlled [17]. However looking 
backward in the past, drug management of risk was 
not that easy to achieve. Indeed, in the early sixties 
48% of the persons with hypertension were aware of it, 
30% under treatment and only 12% controlled [17]. As 
far as cancer prevention is concerned, it is not possible 
to know yet whether a similar shift towards higher 
acceptability will occur as preventive action takes time 
to implement (education, information, communica-
tion) or if cancer risk mitigation is under different de-
cision-making pattern.  
Randomization has been reported to reduce the 
willingness of patients to be involved in clinical trials 
[18]. Interestingly, our results show a high acceptabil-
ity rate for randomization. Three hypotheses may ex-Int. J. Med. Sci. 2008, 5 
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plain this opposition. First a cultural difference [19] 
could steer the meaning of randomization and its 
connection with fate. Second the difference between 
attitudes and behaviors [20]. Lastly maybe some par-
ticipants didn’t really understand the meaning of the 
question, despite the fact that it was the item on which 
attention had been focused on during the pilot phase 
of that survey. An argument against this last hypothe-
sis is that there was no statistical difference in the rate 
according to the level of education (data not shown). 
If confirmed, the major result of our survey is the 
huge impact of the duration of the trial on the accept-
ability rate. People agree with short-term trials of one 
year or less and disagree strongly with longer trials. 
These data are coherent with the observed drop-out 
rates in preventive trials [21]. If confirmed, this pro-
vides advice to “clinical trial designers” and pharma-
ceutical companies to look for intermediate end points 
[22,23] or short-term interventions, which could be 
recurrent. In this respect, for the targeting of apoptosis 
[24], a kind of ‘wash-out’ intervention could therefore 
be both efficient and acceptable. 
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